ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 085,82
-0,84%
Dow Jones
43 586,82
0,37%
DAX
22 393,56
0,58%
Brent Oil
74,415
0,42%
Bitcoin
94 664,58
-1,67%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Actualités

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATRA
DateHeureSourceTitreSymboleSociété
07/02/202522h01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
07/02/202500h34Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATRAAtara Biotherapeutics Inc
29/01/202522h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
27/01/202522h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
21/01/202513h30Business WireAtara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219NASDAQ:ATRAAtara Biotherapeutics Inc
17/01/202522h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
16/01/202514h30Business WireAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)NASDAQ:ATRAAtara Biotherapeutics Inc
27/11/202422h01Business WireAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
18/11/202423h58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
13/11/202422h01Business WireAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
12/11/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
12/11/202422h01Business WireAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
05/11/202422h01Business WireAtara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:ATRAAtara Biotherapeutics Inc
06/09/202400h42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
05/09/202422h07Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ATRAAtara Biotherapeutics Inc
04/09/202422h42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
04/09/202422h01Business WireAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
03/09/202422h16Business WireAtara Biotherapeutics Announces $36 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
12/08/202423h00Business WireAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateNASDAQ:ATRAAtara Biotherapeutics Inc
07/08/202422h01Business WireAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/07/202415h00Business WireAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative DiseaseNASDAQ:ATRAAtara Biotherapeutics Inc
04/07/202401h57Business WireAtara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy ForumNASDAQ:ATRAAtara Biotherapeutics Inc
21/06/202422h01Business WireAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare DiseasesNASDAQ:ATRAAtara Biotherapeutics Inc
17/06/202414h00Business WireAtara Biotherapeutics Announces 1-for-25 Reverse Stock SplitNASDAQ:ATRAAtara Biotherapeutics Inc
05/06/202422h01Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
29/05/202422h01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
23/05/202400h18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202415h25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202422h30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202422h01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATRA

Dernières Valeurs Consultées

EU
ORA
Orange
COIN
AVAXUSD
Avalanche
NASDAQ
GOOGL
Alphabet
EU
CS
Axa
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
NYSE
NKE
Nike
COIN
ADAUSD
Cardano
EU
AI
Air Liquide
EU
SGO
Cie de SaintGobain
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces